Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
10.1002/ijc.24988 Int
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
Duarte, J.-C
In the past years, several studies evaluating the effects of HMB, mainly in cows milk production and composition, found a variety of responses including benefits or no effects
Methods: We retrieved reports of AEs associated with treatment with GLP-1 RAs during the period from the first quarter (Q1) of 2004 to Q1 2023 from the FDA Adverse Event Reporting System (FAERS) database
US$ 20.46
US$ 25.21
US$ 20.38
